The second quarter of 2022 kicked off with a new life sciences company joining the public markets, but not via an IPO or merger. Becton Dickinson on Friday completed the spinoff of its diabetes care business, Embecta, which now trades on the Nasdaq.
The deal will give the Swiss drugmaker control of inclisiran, a drug for which The Medicines Company plans to file for approval in lipid disorders starting this quarter.
Munck Wilson Mandala Partner Greg Howison shared his perspective on some of the legal ramifications around AI, IP, connected devices and the data they generate, in response to emailed questions.
Although it hasn't yet released details, the company announced positive data from two Phase III studies of inclisiran, which it is developing with Alnylam. The drug prevents production of PCSK9, the target of drugs made by Amgen and Sanofi/Regeneron.
Inclisiran, which The Medicines Co. is developing with Alnylam, prevents production of PCSK9, the same protein targeted by two drugs that were the subject of a major patent lawsuit ruling last week. The company plans regulatory filings starting later this year.
Med device startup Onkos Surgical isn't taking on Goliath, it's just taking on one arm. Or a leg for that matter.
Medical technology manufacturer Becton Dickinson (NYSE: BDX) has acquired a collaboration partner that produces handheld, electronic diagnostic devices. They are designed to be used at the point of care in places like physician offices, retail clinics and patient homes. The $40 million deal to take over San Jose healthcare technology company Alverix will help it […]
At the Abarca Forward conference earlier this year, George Van Antwerp, managing director at Deloitte, discussed how social determinants of health and a personalized member experience can improve medication adherence and health outcomes.
Most of us are aware of that medication adherence is a costly problem, but a new report puts it in alarming context and sheds some light on other factors under the [broad] category of medication misuse that are driving up healthcare costs to the tune of $200 billion. The complications stemming from medication misuse lead […]